Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR-T Therapy FT819 in Systemic Lupus Erythematosus
核心洞察
Fate Therapeutics' FT819 off-the-shelf CAR-T therapy demonstrated meaningful disease reduction in 12 systemic lupus erythematosus (搜索) patients with a favorable safety profile and no dose-limiting toxicities.
The therapy achieved up to 78% reduction in disease activity scores at six months, with 5 out of 10 patients achieving clinical remission without intensive conditioning chemotherapy.
The company plans to initiate a registrational trial for FT819 in 2026 following FDA discussions under its Regenerative Medicine Advanced Therapy designation.
Fate Therapeutics presented encouraging Phase 1 clinical data for its off-the-shelf CAR-T cell therapy FT819 in systemic lupus erythematosus (搜索) (SLE) at the 2025 American Society of Hematology Annual Meeting, demonstrating sustained clinical responses and a differentiated safety profile that could transform treatment accessibility for autoimmune diseases.
The San Diego-based biopharmaceutical company reported results from 12 SLE patients treated with FT819, an iPSC-derived CD19 (搜索)-targeting CAR-T therapy designed to overcome limitations of traditional patient-sourced cell therapies through its off-the-shelf availability and uniform composition.
Clinical Efficacy Demonstrates Dose-Response Relationship
The updated clinical data showed progressive improvement in disease activity scores across both dose levels tested. In the lower dose group (360 million cells), mean SLEDAI-2K scores decreased from 15.2 at baseline to 10 at month 3 and 6 at month 6, representing 50% and 70% reductions respectively. The higher dose group (900 million cells) demonstrated even greater improvements, with scores declining from 14.3 at baseline to 6 at month 3 and 4 at month 6, achieving 65% and 78% reductions.
"The updated FT819 clinical data continue to demonstrate meaningful and durable responses with the use of less-intensive conditioning chemotherapy and a differentiated safety profile," said Bob Valamehr, President and CEO of Fate Therapeutics.
Notably, 5 out of 10 patients achieved clinical SLEDAI-2K scores of 0, indicating clinical remission. Two of these patients had previously failed to achieve remission with immunosuppressive agents before receiving FT819. Among patients with lupus nephritis (搜索), both individuals with greater than 3-month follow-up achieved complete renal response at 2 and 6 months respectively.
Safety Profile Supports Broader Patient Access
The therapy demonstrated a favorable safety profile without dose-limiting toxicities or severe complications typically associated with CAR-T therapies. No Grade >2 cytokine release syndrome (CRS), immune cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD) were reported. This safety profile was achieved without intensive conditioning chemotherapy, which typically requires multiple days of combined cyclophosphamide and fludarabine treatment.
The study enrolled patients with significant disease burden, including a median SLE duration of 8.7 years and median of 7 prior therapies, with baseline SLEDAI-2K scores ranging from 8-20. All patients experienced meaningful improvements in fatigue scores, and B-cell depletion was observed with reconstitution toward predominantly naïve cells within three months.
Expanding Access Through International Sites
The trial has expanded to include 14 clinical sites across the United States and United Kingdom, with the first international SLE patient recently treated. This expansion supports the company's goal of providing broad, on-demand patient accessibility to FT819 therapy.
Regulatory Pathway and Next-Generation Programs
Fate Therapeutics is engaged in discussions with the FDA under its Regenerative Medicine Advanced Therapy (RMAT) designation regarding plans to initiate a registrational trial in 2026. The company's iPSC platform enables mass production of uniform cell products that can be stored in inventory for immediate availability.
The company also unveiled preclinical data for two next-generation programs at ASH. FT836 targets stress antigens MICA/B (搜索) combined with daratumumab for multiple myeloma (搜索) treatment, while FT839 (搜索) employs dual-CAR CD19 (搜索)/CD38 (搜索) targeting for B-cell malignancies (搜索) and autoimmune diseases without requiring conditioning chemotherapy.
Platform Technology Advantages
FT819 is manufactured from precisely engineered clonal master iPSC lines, analogous to master cell lines used for monoclonal antibody production. This approach creates well-defined, uniform cell products with low cost of goods and off-the-shelf availability, potentially reaching broader patient populations than traditional autologous CAR-T therapies.
The company's iPSC platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications, establishing a foundation for scalable cellular immunotherapy manufacturing.